Our meta-analysis revealed that BV-based regimens showed a clear trend toward higher PET-2 negative rates, and significantly improved end-of-treatment complete metabolic response rates.
← all excerpts
Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials.
1
—
—